Literature DB >> 8458030

Acadesine: the prototype adenosine regulating agent for reducing myocardial ischaemic injury.

K Mullane1.   

Abstract

Acadesine is the prototype of a new class of therapeutic compounds termed adenosine regulating agents. Acadesine is pharmacologically silent in normal circumstances, but its activity becomes operative during situations of net ATP catabolism, when it increases local adenosine levels. Thus acadesine is able to harness the beneficial effects of this protective autacoid without the limiting side effects associated with using adenosine itself or an adenosine mimetic or transport inhibitor. The demonstrated efficacy of acadesine in various models of myocardial ischaemia and the preliminary clinical results 48 indicate that acadesine and other ARAs could represent important new additions to the cardiologist's armamentarium to combat myocardial ischaemia and its sequelae.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8458030     DOI: 10.1093/cvr/27.1.43

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  15 in total

Review 1.  Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy.

Authors:  Aslan T Turer; Joseph A Hill
Journal:  Am J Cardiol       Date:  2010-08-01       Impact factor: 2.778

Review 2.  Beyond AICA riboside: in search of new specific AMP-activated protein kinase activators.

Authors:  Bruno Guigas; Kei Sakamoto; Nellie Taleux; Sara M Reyna; Nicolas Musi; Benoit Viollet; Louis Hue
Journal:  IUBMB Life       Date:  2009-01       Impact factor: 3.885

3.  AMPK and Akt determine apoptotic cell death following perturbations of one-carbon metabolism by regulating ER stress in acute lymphoblastic leukemia.

Authors:  Jeffim N Kuznetsov; Guy J Leclerc; Gilles M Leclerc; Julio C Barredo
Journal:  Mol Cancer Ther       Date:  2011-01-24       Impact factor: 6.261

Review 4.  Mitochondrial Genetic Disorders: Cell Signaling and Pharmacological Therapies.

Authors:  Fatima Djouadi; Jean Bastin
Journal:  Cells       Date:  2019-03-28       Impact factor: 6.600

Review 5.  Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?

Authors:  R Pofi; D Gianfrilli; R Badagliacca; C Di Dato; M A Venneri; E Giannetta
Journal:  J Endocrinol Invest       Date:  2015-07-05       Impact factor: 4.256

6.  Acadesine inhibits tissue factor induction and thrombus formation by activating the phosphoinositide 3-kinase/Akt signaling pathway.

Authors:  Weiyu Zhang; Jianguo Wang; Huan Wang; Rong Tang; John D Belcher; Benoit Viollet; Jian-Guo Geng; Chunxiang Zhang; Chaodong Wu; Arne Slungaard; Chuhong Zhu; Yuqing Huo
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-02-25       Impact factor: 8.311

7.  AICAR inhibits the Na+/H+ exchanger in rat hearts--possible contribution to cardioprotection.

Authors:  Terence R Moopanar; Xiao-Hui Xiao; Lele Jiang; Zhi-Ping Chen; Bruce E Kemp; David G Allen
Journal:  Pflugers Arch       Date:  2006-09-16       Impact factor: 3.657

8.  AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress.

Authors:  Kazuo Terai; Yoshimune Hiramoto; Mitsuru Masaki; Shoko Sugiyama; Tadashi Kuroda; Masatsugu Hori; Ichiro Kawase; Hisao Hirota
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

9.  Extracellular guanosine regulates extracellular adenosine levels.

Authors:  Edwin K Jackson; Dongmei Cheng; Travis C Jackson; Jonathan D Verrier; Delbert G Gillespie
Journal:  Am J Physiol Cell Physiol       Date:  2012-12-12       Impact factor: 4.249

Review 10.  Adenosine kinase: A key regulator of purinergic physiology.

Authors:  Detlev Boison; Michael F Jarvis
Journal:  Biochem Pharmacol       Date:  2020-11-06       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.